Marksman51
07 Jun 2018
ARTA ARTA, Artilium in which I hold a big chunk received an agreed/recommended take over offer at roughly a premium of 18%. It values the shares of the company at 19.55p. The price this morning is 17-18p. The offer contains cash and some shares of the acquiring company. I’m selling my holding in a minute, I don’t like the new shares. I’m up 33% on my entire large holding within 6 months of purchase. That’ll do nicely for me, thank you very much.Good luck Dr MBtw it’s raining money on me today. It must be an early Christmas. Lol
Nige the snake
07 Jun 2018
portfolio showing over 13% profit now 36,403.40 41,303.20 +4,899.80 +13.46 GBPOverall Total 36,403.40 41,303.20 +4,899.80 +13.46 GBPOverall GBP Total 36,403.40 41,303.20 +4,899.80 +13.46NB.Your cash entries are now held in Other A
Marksman51
07 Jun 2018
APH APH RNS today, great stuff, sp up 4.4%. I’m a happy holder . CushtyDYOR Dr MRNS Number : 6117QAlliance Pharma PLC07 June 2018 For immediate release 07 June 2018 ALLIANCE PHARMA PLC("Alliance" or the "Group"
Positive Opinion on Diclectin Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency ("MHRA" and the Commission on Human Medicines ("CHM", the Marketing Authorisation Application for Diclectin® is now considered approvable. Alliance awaits issue of the formal Marketing Authorisation from the MHRA in the coming weeks, with UK launch anticipated to be in the autumn of this year. Diclectin, a prescription treatment for nausea and vomiting of pregnancy, was in-licensed from Duchesnay Inc. of Canada ("Duchesnay" for the UK in 2015 and for a further nine European territories in 2016*. Diclectin has a well-established efficacy and safety profile and is regarded as the standard of care for nausea and vomiting of pregnancy in Canada, where it has been used for over 40 years and has been prescribed for more than 30 million women. In 2013, Diclectin ("Diclegis" was approved in the United States with the highest possible safety rating for drugs used during pregnancy, FDA Category A, and has since been approved in Israel, South Korea and Singapore. Following the approval of Diclectin in the UK, Alliance expects to commence the filing of the necessary applications for regulatory approvals for further European territories in advance of launches later in 2019. Commenting on the news, Peter Butterfield, Alliance Pharma's Chief Executive Officer, said:"We are delighted by this news and look forward to launching Diclectin later this year. There are currently no licensed treatments for nausea and vomiting of pregnancy in the UK, highlighting a clear unmet need for patients and clinicians. For Alliance, Diclectin represents a sizeable mid-term opportunity and also allows us to further leverage our European footprint." Éric Gervais, Duchesnay's Executive Vice-President, added:"Nausea and vomiting of pregnancy is a common medical condition that can affect up to 80% of all pregnant women. It can be debilitating and can worsen if left untreated. We continue to support Alliance in their efforts to provide a licensed treatment, which has a proven safety and efficacy profile, for women in the UK suffering from morning sickness." *Austria, Belgium, France, Germany, Italy, Luxembourg, Netherlands, Republic of Ireland, Switzerland,
Marksman51
07 Jun 2018
IPX Great RNS from ipx today, I’m a holder of two tranches here, sp up 5% , Cushty.DYOR, Dr MImpax Asset Management Group07 Jun 2018 07:56:50Impax Asset MngmntRNS Number : 6215QImpax Asset Management Group plc07 June 2018 Impax Asset Management Group plcInterim results to 31 March 2018 London, 7 June 2018 - Impax Asset Management Group plc ("Impax" or the "Company", the specialist investor focused on a more sustainable global economy, today announces interim results for the six months to 31 March 2018 (the "Period". Ian Simm, Chief Executive, commented: "I am pleased to report on a successful first half of the year. Alongside robust investment performance and net inflows of £1 billion, we completed the acquisition of Pax World Management LLC ("Pax", further extending our investment management capabilities and client base in North America. The Company's strong financial results support a 57% increase in the interim dividend to 1.1 pence per share. In addition, following the realisation of carried interest proceeds from Impax's second private equity infrastructure fund, the board has declared a special dividend of 2.6 pence per share. As asset owners around the world seek higher levels of exposure to the companies leading the transition to a more sustainable economy, Impax remains well placed for further profitable growth." H1 business highlights · Completion of the acquisition of Pax1 · AUM2 increased 51% to £11.0 billion; £2.9 billion attributable to Pax World Funds, increasing to £11.8 billion as at 31 May 2018 · Total net inflows of over £1 billion, predominantly from clients in continental Europe and North America · Final close of Impax's third private equity infrastructure fund with assets of €357million H1 financial highlights · Interim dividend increased by 57% to 1.1 pence per share · Special dividend of 2.6 pence per share payable as result of outstanding performance of second private equity infrastructure fund. · Revenue: £25.7 million3 (H1, 2017: £13.9m) · Profit before tax: £5.5 million (H1, 2017: £2.4m) · Adjusted earnings per share: 4.83p (H1, 2017: 1.94p) The presentation for shareholders and analysts will be available to view on the Company's website later this morning: [link] information communicated in this announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.
Marksman51
07 Jun 2018
PLUS PLUS RNS today, trading materially higher than expectations. Brokers price target 1994p. A lot of people have bought this share since I started recommending it at 800p a few months ago. I know our friend Moonsurfer is a holder, well done to all of us holders.DYOR Dr MStockMarketWire | Thu, 7th June 2018 - 07:19Plus500 said its business continues to trade strongly and materially increased expectations for its financial performance for the year to 31 December 2018.As announced in the company's preliminary results on 14 February and the trading update on 1 May, Plus500 had a strong start to the financial year; mainly due to a period of relative volatility in the markets and high levels of trading in the company's cryptocurrency CFDs offering.The Bbard believes these factors encouraged high levels of new customer sign-ups and therefore record trading in Q1 2018.While market conditions have returned to more normal levels in Q2 2018, trading has nevertheless been materially ahead of management expectations.As previously announced in the 1 May 2018 trading update, the full impact of the ESMA measures, which are now confirmed to take effect from 1 August 2018, are difficult to assess.Similarly, the Group's performance could also be impacted by the rate at which customers request to be reclassified, and are accepted, as elective professional clients.The board will assess the impact of the ESMA measures on current and future years' performance once the ESMA measures are fully operational and will make further announcements as appropriate.CEO Asaf Elimelech commented: "We are pleased with the continued strong financial performance made despite market conditions returning to more normal levels during this period."We remain confident about the future prospects for the company."
Nige the snake
07 Jun 2018
FRR.L great RNS not a holder but worth a look.
Nige the snake
07 Jun 2018
Re: SOU another reason to buy the key words are....without additional equity dilution."
Nige the snake
07 Jun 2018
SOU another reason to buy Sound Energy's CEO James Parsons commented: "This is a hugely important milestone for our Company and I am delighted that Sound Energy is playing such a pivotal role in unlocking the first significant scale indigenous gas production in Morocco. should be in the top risers todayFor Sound Energy and its shareholders, this innovative BOOT structure means that the Company is now firmly on the pathway to commercialising our existing and future gas resources in Eastern Morocco, all without additional equity dilution." The Consortium will shortly begin front end engineering and design ("FEED" on a gas processing plant and a 20 inch gas pipeline intended to deliver an estimated 60 mmscf/d of gas to the Gas Maghreb-Europe pipeline system, some 120km away (the "Project"
penhome
06 Jun 2018
New ii website This coming weekend.Check out banner at top of page.Pen
lebehnon
06 Jun 2018
Re: MTCH The Dr is doing well he has loads of cash has a system that works small losses when he buys cr-p big gains as adds to winners has the money to trade this way / can afford to lose is bored - this gives him a kick. He is doing well as picks shares that the robot traders are picking. Value investing takes longer has less turnover may do as well if you are young and can live that long. The Dr is old has not got the time to wait - would be boring. I get what he is doing. The Dr likes you to know how well he is doing - he genuinely wants you all to do as well as him. I annoy him all the time. You are not on ignore anymore by the way. I don't read that many posts anymore. Pick and choose. Robbie tends to pick rising shares 52 week break outs using ADVFN ( paid info) He dumps losers adds to winners keeps them for as long as possible. Yes we could all do what the Dr is doing / why get annoyed am sure he would invite you round to inspect his portfolio and prove he is not losing. He admits when he is doing badly - He is definitely winning big imv.
Marksman51
06 Jun 2018
iamsharecrazy iamsharecrazyThis is an invitation for you to rejoin this bb.Please be courteous to the wider readership of this bb.Please tell us the shares you hold.Please tell us the shares you bought recently ie last 6 weeks and why you bought them.Please tell us the shares you sold and why. Please be helpful to the readership of this bb so they can make more money on their stock market investments. Can you do that?You don’t need to have a pop at me. Just be helpful to people in here.I trust this will be ok with you to do in the next few days.Thank you. Good luckDr M
Marksman51
06 Jun 2018
Re: MTCH Crazy manYou can say anything you like. I rely on my bottom line of £££ gained v £££ lost from my shares purchases and sales.I’m doing very well thank you very much.That’s why my portfolio is at an all time high. No hearsay, just fact.I’m off now to do the Conga on my patio.You are seriously mentally deranged. I hope you’ll get better soon. Dr M
Marksman51
06 Jun 2018
Re: DR 4 USA Techs for you LebGood stuff. To be honest, I had iamsharecrazy on ignore but brought him back in last weekend. Just to see if he can be rescued and be re admitted into the civilised western society we’re in. I will tolerate him one more time.The truth is this. We are serious investors in here trying to make more money by helping each other using our varying skills and methods of investment.What does iamsharecrazy bring to this discussion board in this respect? Nothing. Zero. Zilch. Very sad man indeed. And he’s voted up by Loadsadough. Oh dear Loadsadough; get your brain back inside your skull please.Dr M
IAmShareCrazy
06 Jun 2018
Re: MTCH You seem a bit one dimensional/robotic. Never trust a Dr! They are more corrupt than most.
IAmShareCrazy
06 Jun 2018
Re: MTCH You regurgitate most shares to the board I have already mentioned and most people can find anyway. Gan and MacFarlane the most recent. Are you a one track record with your cut and paste drivel. You say buy a rising share, usually not at the right time because if it goes against you when buying overbought shares you are in deep water. Have you anything new or interesting to add?
